Overview

A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease

Status:
Withdrawn
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy in topical administration of differing dosing regimens of ISV-101 (Bromfenac in DuraSite® ophthalmic solution) compared to Vehicle and DuraSite alone.
Phase:
Phase 2
Details
Lead Sponsor:
InSite Vision
Sun Pharma Global FZE
Treatments:
Bromfenac